Intravitreal voriconazole

An electroretinographic and histopathologic study

Hua Gao, Mark Pennesi, Kekul Shah, Xiaoxi Qiao, Seenu M. Hariprasad, William F. Mieler, Samuel M. Wu, Eric R. Holz

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Background: Voriconazole, a novel triazole antifungal agent, presents potent activity against a broad spectrum of yeast and molds. Objective: To determine whether voriconazole could be safely used as an intravitreal agent in the treatment of fungal endophthalmitis. Methods: Retinal toxicity of voriconazole was examined in a rodent animal model. Voriconazole solutions were serially diluted and injected intravitreally into the eyes of normal adult Sprague-Dawley rats so that the final intravitreal concentrations were 5 μg/mL, 10 μg/mL, 25 μg/mL, 50 μg/mL, and 500 μg/mL (n=3 for each concentration group). Saline was injected into the fellow eyes of all animals as controls. Three weeks after injections, electroretinograms were measured, and eyes were subsequently enucleated for histologic examination. Results: In electroretinographic studies, maximum scotopic b-wave, intensity needed for half saturation, and saturated a-wave amplitude were measured. There was no statistically significant difference in these parameters recorded between control eyes and voriconazole-injected eyes in any concentration groups. Histologic examination with light microscopy did not reveal any retinal abnormality in the eyes with 5 to 25 μg/mL of intravitreal voriconazole. In the eyes with 50 μg/mL and 500 μ/mL of voriconazole, small foci of retinal necrosis were occasionally observed in the outer retina, especially in the eyes with 500 μg/mL of voriconazole. Conclusions: Our results demonstrate that intravitreal voriconazole of up to 25 mg/mL causes no electroretinographic change or histologic abnormality in rat retinas. This indicates that voriconazole is a safe antifungal agent for intravitreal injection in rodents and may be used in the treatment of human fungal endophthalmitis following further study.

Original languageEnglish (US)
Pages (from-to)1687-1692
Number of pages6
JournalArchives of Ophthalmology
Volume122
Issue number11
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Endophthalmitis
Antifungal Agents
Retina
Rodentia
Eye Abnormalities
Voriconazole
Intravitreal Injections
Triazoles
Sprague Dawley Rats
Microscopy
Fungi
Necrosis
Animal Models
Yeasts
Light
Injections
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Gao, H., Pennesi, M., Shah, K., Qiao, X., Hariprasad, S. M., Mieler, W. F., ... Holz, E. R. (2004). Intravitreal voriconazole: An electroretinographic and histopathologic study. Archives of Ophthalmology, 122(11), 1687-1692. https://doi.org/10.1001/archopht.122.11.1687

Intravitreal voriconazole : An electroretinographic and histopathologic study. / Gao, Hua; Pennesi, Mark; Shah, Kekul; Qiao, Xiaoxi; Hariprasad, Seenu M.; Mieler, William F.; Wu, Samuel M.; Holz, Eric R.

In: Archives of Ophthalmology, Vol. 122, No. 11, 11.2004, p. 1687-1692.

Research output: Contribution to journalArticle

Gao, H, Pennesi, M, Shah, K, Qiao, X, Hariprasad, SM, Mieler, WF, Wu, SM & Holz, ER 2004, 'Intravitreal voriconazole: An electroretinographic and histopathologic study', Archives of Ophthalmology, vol. 122, no. 11, pp. 1687-1692. https://doi.org/10.1001/archopht.122.11.1687
Gao, Hua ; Pennesi, Mark ; Shah, Kekul ; Qiao, Xiaoxi ; Hariprasad, Seenu M. ; Mieler, William F. ; Wu, Samuel M. ; Holz, Eric R. / Intravitreal voriconazole : An electroretinographic and histopathologic study. In: Archives of Ophthalmology. 2004 ; Vol. 122, No. 11. pp. 1687-1692.
@article{dbf7333152a543bab56144b7b24678e2,
title = "Intravitreal voriconazole: An electroretinographic and histopathologic study",
abstract = "Background: Voriconazole, a novel triazole antifungal agent, presents potent activity against a broad spectrum of yeast and molds. Objective: To determine whether voriconazole could be safely used as an intravitreal agent in the treatment of fungal endophthalmitis. Methods: Retinal toxicity of voriconazole was examined in a rodent animal model. Voriconazole solutions were serially diluted and injected intravitreally into the eyes of normal adult Sprague-Dawley rats so that the final intravitreal concentrations were 5 μg/mL, 10 μg/mL, 25 μg/mL, 50 μg/mL, and 500 μg/mL (n=3 for each concentration group). Saline was injected into the fellow eyes of all animals as controls. Three weeks after injections, electroretinograms were measured, and eyes were subsequently enucleated for histologic examination. Results: In electroretinographic studies, maximum scotopic b-wave, intensity needed for half saturation, and saturated a-wave amplitude were measured. There was no statistically significant difference in these parameters recorded between control eyes and voriconazole-injected eyes in any concentration groups. Histologic examination with light microscopy did not reveal any retinal abnormality in the eyes with 5 to 25 μg/mL of intravitreal voriconazole. In the eyes with 50 μg/mL and 500 μ/mL of voriconazole, small foci of retinal necrosis were occasionally observed in the outer retina, especially in the eyes with 500 μg/mL of voriconazole. Conclusions: Our results demonstrate that intravitreal voriconazole of up to 25 mg/mL causes no electroretinographic change or histologic abnormality in rat retinas. This indicates that voriconazole is a safe antifungal agent for intravitreal injection in rodents and may be used in the treatment of human fungal endophthalmitis following further study.",
author = "Hua Gao and Mark Pennesi and Kekul Shah and Xiaoxi Qiao and Hariprasad, {Seenu M.} and Mieler, {William F.} and Wu, {Samuel M.} and Holz, {Eric R.}",
year = "2004",
month = "11",
doi = "10.1001/archopht.122.11.1687",
language = "English (US)",
volume = "122",
pages = "1687--1692",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Intravitreal voriconazole

T2 - An electroretinographic and histopathologic study

AU - Gao, Hua

AU - Pennesi, Mark

AU - Shah, Kekul

AU - Qiao, Xiaoxi

AU - Hariprasad, Seenu M.

AU - Mieler, William F.

AU - Wu, Samuel M.

AU - Holz, Eric R.

PY - 2004/11

Y1 - 2004/11

N2 - Background: Voriconazole, a novel triazole antifungal agent, presents potent activity against a broad spectrum of yeast and molds. Objective: To determine whether voriconazole could be safely used as an intravitreal agent in the treatment of fungal endophthalmitis. Methods: Retinal toxicity of voriconazole was examined in a rodent animal model. Voriconazole solutions were serially diluted and injected intravitreally into the eyes of normal adult Sprague-Dawley rats so that the final intravitreal concentrations were 5 μg/mL, 10 μg/mL, 25 μg/mL, 50 μg/mL, and 500 μg/mL (n=3 for each concentration group). Saline was injected into the fellow eyes of all animals as controls. Three weeks after injections, electroretinograms were measured, and eyes were subsequently enucleated for histologic examination. Results: In electroretinographic studies, maximum scotopic b-wave, intensity needed for half saturation, and saturated a-wave amplitude were measured. There was no statistically significant difference in these parameters recorded between control eyes and voriconazole-injected eyes in any concentration groups. Histologic examination with light microscopy did not reveal any retinal abnormality in the eyes with 5 to 25 μg/mL of intravitreal voriconazole. In the eyes with 50 μg/mL and 500 μ/mL of voriconazole, small foci of retinal necrosis were occasionally observed in the outer retina, especially in the eyes with 500 μg/mL of voriconazole. Conclusions: Our results demonstrate that intravitreal voriconazole of up to 25 mg/mL causes no electroretinographic change or histologic abnormality in rat retinas. This indicates that voriconazole is a safe antifungal agent for intravitreal injection in rodents and may be used in the treatment of human fungal endophthalmitis following further study.

AB - Background: Voriconazole, a novel triazole antifungal agent, presents potent activity against a broad spectrum of yeast and molds. Objective: To determine whether voriconazole could be safely used as an intravitreal agent in the treatment of fungal endophthalmitis. Methods: Retinal toxicity of voriconazole was examined in a rodent animal model. Voriconazole solutions were serially diluted and injected intravitreally into the eyes of normal adult Sprague-Dawley rats so that the final intravitreal concentrations were 5 μg/mL, 10 μg/mL, 25 μg/mL, 50 μg/mL, and 500 μg/mL (n=3 for each concentration group). Saline was injected into the fellow eyes of all animals as controls. Three weeks after injections, electroretinograms were measured, and eyes were subsequently enucleated for histologic examination. Results: In electroretinographic studies, maximum scotopic b-wave, intensity needed for half saturation, and saturated a-wave amplitude were measured. There was no statistically significant difference in these parameters recorded between control eyes and voriconazole-injected eyes in any concentration groups. Histologic examination with light microscopy did not reveal any retinal abnormality in the eyes with 5 to 25 μg/mL of intravitreal voriconazole. In the eyes with 50 μg/mL and 500 μ/mL of voriconazole, small foci of retinal necrosis were occasionally observed in the outer retina, especially in the eyes with 500 μg/mL of voriconazole. Conclusions: Our results demonstrate that intravitreal voriconazole of up to 25 mg/mL causes no electroretinographic change or histologic abnormality in rat retinas. This indicates that voriconazole is a safe antifungal agent for intravitreal injection in rodents and may be used in the treatment of human fungal endophthalmitis following further study.

UR - http://www.scopus.com/inward/record.url?scp=8144231422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8144231422&partnerID=8YFLogxK

U2 - 10.1001/archopht.122.11.1687

DO - 10.1001/archopht.122.11.1687

M3 - Article

VL - 122

SP - 1687

EP - 1692

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 11

ER -